Ketogenic Diet Alters Dopaminergic Activity in the Mouse Cortex [post-print] by Church, William H. et al.
Trinity College
Trinity College Digital Repository
Faculty Scholarship
4-2014








Follow this and additional works at: http://digitalrepository.trincoll.edu/facpub
Part of the Neurosciences Commons
Revised Manuscript NSL-14-113 







Ketogenic Diet Alters Dopaminergic Activity in 
the Mouse Cortex 
 
 
William H. Church, Ryan E. Adams and Livia S. Wyss 
Department of Chemistry and Neuroscience Program 






William H. Church, Ph.D. 
Department of Chemistry and Neuroscience Program 
Trinity College 
300 Summit Street 






The work described in this paper has been carried out in accordance with the Uniform Requirements for 
manuscripts submitted to Biomedical Journals 








Abstract:   
      The present study was conducted to determine if the ketogenic diet altered basal levels of 
monoamine neurotransmitters in mice. The catecholamines dopamine (DA) and norephinephrine 
(NE) and the indolamine serotonin (5HT) were quantified postmortem in six different brain 
regions of adult mice fed a ketogenic diet for 3 weeks. The dopamine metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and the serotonin 
metabolite 5-hydroxyindole acetic acid (5HIAA) were also measured.  Tissue punches were 
collected bilaterally from the motor cortex, somatosensory cortex, nucleus accumbens, anterior 
caudate-putamen, posterior caudate-putamen and the midbrain.  Dopaminergic activity, as 
measured by the dopamine metabolites to dopamine content ratio – ([DOPAC] + [HVA])/[DA] - 
was significantly increased in the motor and somatosensory cortex regions of mice fed the 
ketogenic diet when compared to those same areas in brains of mice fed a normal diet.  These 
results indicate that the ketogenic diet alters the activity of the meso-cortical dopaminergic 
system, which may contribute to the diet's therapeutic effect in reducing epileptic seizure 
activity. 









  Epilepsy is a predominant neurological disorder which induces recurrent episodes of 
convulsive seizures, loss of consciousness, sensory disturbances and abnormal behavior. The 
ketogenic diet is a high fat, low protein and carbohydrate diet utilized as a non-pharmacological 
therapeutic alternative for individuals suffering from drug resistant epilepsy [1,2].  While the 
exact neuronal mechanism by which the ketogenic diet induces its therapeutic effect remains 
unclear, recent research suggests an involvement of monoamine neurotransmitters [3,4,5], 
adenosine [6,7,8] and glutamatergic transmitter systems [9,10] within the central nervous system.  
 In addition to affecting numerous chemical systems in the CNS, the ketogenic diet has 
been reported to selectively impact specific brain structures.  Zarnowski et al. [11] have shown 
that the levels of the tryptophan metabolite kynurenic acid were increased in the hippocampus 
and striatum, but not the cortex of female rats fed a ketogenic diet for 21 days.  Alternatively, 
Cantello et al. [12] reported that the ketogenic diet increased inhibition of neuronal activity in the 
cerebral cortex of non-epileptic humans.  To evaluate if the ketogenic diet altered basal 
monoamine neurotransmitter content in a region specific manner, the present study measured the 
concentrations of norepinephrine (NE), dopamine (DA), serotonin (5-HT), 3,4-
dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindole acetic acid (5HIAA) and homovanillic 
acid (HVA) in the brains of mice maintained on a three week ketogenic diet. The endogenous 
levels of these neuroactive compounds were determined in the motor cortex (MC), 
somatosensory cortex (SC), nucleus accumbens (NA), anterior and posterior caudate putamen 
(ACPu and PCPu, respectively) and the midbrain (MB) using micropunch sampling coupled with 
separation and quantification by high performance liquid chromatography with electrochemical 
and UV detection. 
Material and Methods:  
 All animal care and use and surgical procedures were approved by the Institutional 
Animal Care and Use Committee of Trinity College and are in accordance with the National 
Institutes of  Health Guide for the Care and Use of Laboratory Animals.  Discrete brain region 
tissue collection and biogenic amine content determination was conducted as previously 




ketogenic diet (#F3666 Bioserve, Frenchtown NJ USA) or control diet (LabDiet 5001, 
Pharmaserv, Framingham, MA USA).  Changes in blood glucose and β-hydroxybutyrate levels 
between control and KD mice were observed (140.5±22.2 mg/dL v. 78.8±18.8 mg/dL and 
0.26±0.1mM v. 2.8±1.4mM, respectively).  Naïve mice were decapitated and whole brains were 
quickly dissected and collected into -20°C isopentane. Time from decapitation to immersion in 
isopentane was 30-40 seconds. To ensure similar dissection technique for all animals and 
treatment groups, all dissections were performed by the same experimenter.  After freezing, 
brains were removed from isopentane and stored at -80°C until punch collection.  Bilateral tissue 
punches (1 mm thick, 1 mm diameter) were acquired from the motor cortex, somatosensory 
cortex, nucleus accumbens, anterior caudate, posterior caudate, and the midbrain. Specific brain 
sites were identified using a standard mouse atlas [15].   The samples were homogenized in 400 
µL of ethanol containing 10 µL of anti-oxidant solution [dihydroxybenzyl amine (DHBA; 
0.011mg/100mL; internal standard), EDTA (0.02mg/100mL), sodium metabisulfite 
(0.1mg/100mL) in 6mM HCl] and then centrifuged at 12,000 xg for 10 minutes.  The supernatant 
samples were filtered through a 0.2 µm nylon disposable syringe filter and centrifuged rotovaped 
to dryness (45°C and 0.1 bar; Centrivap Concentrator, Labconco, Kansas City, MO USA).  
Samples were then reconstituted in 1000 µL of phosphate buffer (pH= 7.4) and stored at -80 °C 
until analyzed by HPLC.     
 The neuroactive compounds were separated on a reverse-phase HPLC system with 
electrochemical and UV detection configured in series.  Separation was carried out on a 150 x 
2.00 mm LUNA 5µm C18 column (Phenomenex, Torrence, CA USA) using an acetonitrile/ 
phosphate buffer with ion pairing agent mobile phase (MD-TM; Thermo Scientific) delivered at 
a flow rate of  0.5 mL/min. Dual electrochemical detection (ESA Coulochem III; E1app= -150 
mV; E2app= +300 mV; Thermo Scientific, Sunnyvale, CA  USA ) and dual wavelength UV 
detection ( λ1= 245nm; λ2= 280 nm; BioAnalytical Systems, West Lafayette, IN USA) were used 
to quantify the compounds of interest using the internal standard calibration method. 
Chromatographic data was collected, stored, and analyzed using EZ Chrom chromatography 
software (Thermo Scientific). Protein content of tissue punches was determined by the Modified 





 Differences in brain tissue levels of the biogenic amines were evaluated using a two-way 
ANOVA with post-hoc comparisons (n=6-9 brains per diet group; GraphPad Prism 4.0, 
GraphPad Software, Inc. San Diego, CA, USA).   
 
Results 
 A three week KD regimen did not alter the tissue levels of NE, DA, 5HT, DOPAC, HVA, 
or 5HIAA in any of the brain regions analyzed (Table 1).  The KD did result in a brain region-
specific increase in the activity of DA neurons as measured by the metabolic ratio.  Figure 1A 
shows that mice fed a ketogenic diet had a significantly higher dopaminergic metabolic ratio (the 
ratio of the tissue levels of the major dopamine metabolites, DOPAC and HVA, to the tissue 
level of DA) in the motor cortex and somatosensory cortex regions (p<0.001 and p< 0.05, 
respectively).  In the motor cortex, the ratio increased 71% , from a value of 3.66 to a value of 
6.27, over controls.  In the somatosensory cortex the ratio increased 151%, from a value of 1.14 
to a value of 2.86, over controls.  An increase was also observed in the midbrain region of mice 
fed a KD that approached significance (2.69 vs. 4.29; p=0.053).  There was no difference in the 
serotonin metabolic ratio ([5HIAA]/ [5HT]) between diet groups in any brain region sampled 
(Figure 1B). 
Discussion 
 Numerous studies utilizing animal models to study the effect of the KD have recently 
been reported (see review [16]).  However, little is known about the effects of the ketogenic diet 
on the neurochemical content in brain regions in these models.  In the present study, the steady-
state tissue levels of the major monoamine neurotransmitters NE, DA, and 5-HT were not 
changed in six different brain regions by a 3-week regimen of the low-fat, high-carbohydrate KD 
(Table 1).  Similar results have recently been reported showing no change in tissue dopamine 
level in the striatum of mice fed a KD for 2 weeks [17].  Kynurenic acid, a metabolite of 
tryptophan (serotonin precursor), was shown to be increased in the hippocampus and striatum but 




increase in the dopaminergic metabolic ratio was shown to be altered in a region-specific manner 
by the KD (Figure 1). 
 The dopaminergic system has been clearly identified as having seizure-modulating 
effects [18].  This modulating effect is very brain region and dopamine receptor subtype specific.   
It was recently reported that dopamine, acting through D1 receptors, decreased neuronal activity 
in the rat cortex [19].  Local application of dopamine has been shown to inhibited spontaneous 
firing rates in pyramidal tract neurons in the rodent motor cortex [20].  In the current study, the 
ketogenic diet altered cortical dopamine activity as measured by an increase in the metabolite-to-
transmitter ratio.  An increase in this ratio is generally accepted to be representative of an 
increase in dopamine turnover produced by an increase in dopamine release.   Increased 
inhibition of cortical neuronal activity as a result of increased dopamine release presents a 
possible mechanism for the KD's therapeutic effect.   Using trans-cranial magnetic stimulation 
(TMS), Cantello et al. [12] have reported an increase in inhibition, as determined by an 
enhancement of measured intra-cortical inhibition (SICI), in the cerebral cortex of normal 
humans fed a KD. Inhibition of cortical neurons by dopamine has been reported in humans[21].   
In the present study, a significant increase in dopaminergic neuronal activity, as measured by the 
metabolites-to-neurotransmitter ratio, was found in the motor and sensory cortex regions of mice 
fed a KD for three weeks (Figure 1A). Thus, it can be proposed that the KD acts directly on 
meso-cortical dopaminerigic neurons  and that subsequent increased cortical inhibition via 
increased meso-cortical DA activity may contribute to the anti-seizure properties of the KD.  
   Alternatively, the observed increase in cortical dopaminergic activity may have been 
generated through an indirect pathway involving elevated adenosine and the glutamate-dopamine 
synapse within the ventral tegmental area (VTA).  Recently an increase in adenosine levels in 
neuronal tissue and subsequent increase in A1 receptors has been proposed as a mechanism 
responsible for altered cortical activity following a KD [7, 22]. Adenosine was shown to 
selectively inhibit mGluR IPSPs in VTA dopamine neurons via A1 receptor antagonism [23].  
The authors suggest that this would result in more effective burst firing, thereby resulting in an 
increase in dopamine neuronal activity. The KD could therefore produce its therapeutic effect 
through an increase in adenosine and subsequent stimulation of A1 receptors on glutamatergic 
afferents which would result in the disinhibition of the VTA dopaminergic neurons.  




hydroxybutarate was used as an energy source for the neurons, resulting in a decrease in 
neuronal glutamate content [24].  This decrease in glutamate release as a result of the energy-
source change produced by the KD would also result in a disinhibition of the VTA dopaminergic 
neurons and the observed increase in cortical dopaminergic metabolic ratio. 
 It is to be noted that the KD used in this study contained a significantly higher amount of 
the antioxidant vitamin E (244 IU/kg compared to 42 IU/kg).  Sharma and Nehru [25] recently 
reported that rats administered vitamin E (100 IU/kg/day i.m.) for 35 days had increased levels 
of dopamine in the midbrain.  Future investigations to elucidate the mechanism responsible for 
the therapeutic effect of the KD will have to include the impact of increased dietary antioxidants. 
 To our knowledge, the current report is the first to evaluate the effect of a chronic KD on 
tissue levels of monoamine neurotransmitters in multiple brain regions of experimental animals.  
While no change in the tissue content of neurotransmitters or metabolites was observed after 
three weeks on the KD, the observed increase in the metabolic ratio for the dopaminergic system 
within the motor and somatosensory cortex suggests involvement of the meso-cortical 
dopaminergic system in the anti-convulsive effect of the KD.  Evaluation of KD-induced cellular 
metabolism changes and the above mentioned neurotransmitter systems within this localized 
region may provide insight into the therapeutic differences seen between the KD and standard 
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Table 1 –  Neurochemical content from selected brain regions of mice fed either a normal chow 





NE DA 5HT DOPAC HVA 5HIAA 
Control Ketogenic Control Ketogenic Control Ketogenic Control Ketogenic Control Ketogenic Control Ketogenic 
MC 
29.6 
(4.1) 
38.5 
(10.4) 
33.1 
(9.3) 
20.5 
(9.6) 
32.0 
(5.4) 
32.5 
(4.4) 
8.7 
(2.1) 
12.1 
(3.8) 
62.9 
(7.8) 
90.6 
(30.7) 
17.4 
(3.0) 
17.2 
(5.6) 
SC 
35.5 
(9.4) 
38.4 
(9.4) 
65.4 
(10.6) 
61.8 
(24.5) 
35.9 
(7.1) 
45.7 
(12.7) 
18.9 
(5.0) 
18.4 
(5.5) 
64.3 
(7.7) 
113.5 
(38.0) 
17.7 
(3.9) 
22.7 
(6.9) 
NA 
31.2 
(8.5) 
27.6 
(3.6) 
231.9 
(31.5) 
233.8 
(48.7) 
33.7 
(5.5) 
38.9 
(7.5) 
30.5 
(4.8) 
37.5 
(8.7) 
57.3 
(12.1) 
75.9 
(14.1) 
18.4 
(4.0) 
17.0 
(3.8) 
ACPu 
32.4 
(11.1) 
22.6 
(42) 
289.9 
(54.6) 
281.2 
(45.4) 
24.6 
(7.8) 
29.7 
(6.5) 
37.2 
(7.4) 
35.7 
(9.1) 
88.8 
(21.9) 
92.9 
(27.4) 
18.7 
(5.5) 
14.1 
(2.6) 
PCPu 
20.8 
(4.3) 
31.2 
(8.2) 
132.3 
(16.8) 
206.9 
(63.8) 
30.2 
(5.9) 
39.1 
(8.3) 
15.5 
(4.3) 
27.5 
(4.4) 
52.1 
(11.8) 
93.1 
(18.5) 
15.8 
(4.0) 
19.5 
(4.1) 
MB 
47.0 
(81) 
61.9 
(8.3) 
25.2 
(5.1) 
20.1 
(4.3) 
37.9 
(7.7) 
35.1 
(7.6) 
12.5 
(2.1) 
16.4 
(3.5) 
51.5 
(8.1) 
76.6 
(13.9) 
22.7 
(3.5) 
26.2 
(4.0) 
 
 
